X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (828) 828
Publication (72) 72
Book Chapter (16) 16
Book Review (14) 14
Book / eBook (5) 5
Dissertation (3) 3
Conference Proceeding (2) 2
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (531) 531
male (322) 322
index medicus (310) 310
female (220) 220
cholesterol-lowering drugs (202) 202
middle aged (196) 196
cholesterol-lowering therapy (177) 177
statins (172) 172
animals (167) 167
cardiac & cardiovascular systems (167) 167
pharmacology & pharmacy (162) 162
cholesterol (153) 153
aged (148) 148
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (147) 147
hypercholesterolemia (131) 131
atherosclerosis (127) 127
risk factors (122) 122
adult (118) 118
cholesterol, ldl - blood (111) 111
coronary-heart-disease (109) 109
anticholesteremic agents - therapeutic use (103) 103
cholesterol - blood (103) 103
hypercholesterolemia - drug therapy (102) 102
treatment outcome (95) 95
peripheral vascular disease (89) 89
prevention (84) 84
simvastatin (84) 84
lipids (82) 82
risk (82) 82
cholesterol lowering (74) 74
cardiovascular-disease (71) 71
pravastatin (71) 71
nutrition & dietetics (70) 70
myocardial-infarction (68) 68
anticholesteremic agents - pharmacology (64) 64
hydroxymethylglutaryl-coa reductase inhibitors - pharmacology (60) 60
rats (60) 60
serum-cholesterol (60) 60
cardiovascular disease (59) 59
atorvastatin (57) 57
low-density-lipoprotein (57) 57
biochemistry & molecular biology (56) 56
coronary heart disease (56) 56
diet (56) 56
hypercholesterolemia - blood (56) 56
coronary-artery-disease (55) 55
analysis (52) 52
cholesterol, hdl - blood (52) 52
endothelium (52) 52
low density lipoproteins (52) 52
anticholesteremic agents (51) 51
double-blind method (51) 51
research (51) 51
health aspects (50) 50
heart-disease (50) 50
lipids - blood (50) 50
mortality (50) 50
c-reactive protein (48) 48
endothelium, vascular - drug effects (47) 47
lipoproteins (47) 47
cardiovascular diseases - prevention & control (46) 46
medicine, general & internal (46) 46
statin (46) 46
risk-factors (45) 45
cardiovascular (44) 44
cardiovascular diseases (44) 44
care and treatment (44) 44
nitric-oxide synthase (44) 44
therapy (44) 44
triglycerides - blood (44) 44
cholesterol-lowering foods (43) 43
prostate cancer (43) 43
metaanalysis (42) 42
metabolism (41) 41
anticholesteremic agents - administration & dosage (40) 40
article (40) 40
endothelium, vascular - physiopathology (40) 40
lovastatin (40) 40
safety (40) 40
drug therapy (39) 39
efficacy (39) 39
ezetimibe (39) 39
cholesterol-lowering treatment (38) 38
drug therapy, combination (38) 38
medicine, research & experimental (38) 38
oncology (38) 38
familial hypercholesterolemia (37) 37
hypolipidemic agents - therapeutic use (37) 37
randomized controlled trials as topic (37) 37
atorvastatin calcium (36) 36
endothelial function (36) 36
food science & technology (36) 36
dose-response relationship, drug (35) 35
hmg-coa reductase (35) 35
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (35) 35
men (35) 35
coronary artery disease (34) 34
time factors (34) 34
cholesterol - metabolism (33) 33
disease (33) 33
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (822) 822
French (9) 9
German (6) 6
Japanese (5) 5
Russian (3) 3
Spanish (3) 3
Korean (2) 2
Chinese (1) 1
Hungarian (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2009, ISBN 9780195323573, xvii, 201
Book
Circulation, ISSN 0009-7322, 04/2007, Volume 115, Issue 16, pp. 2128 - 2135
Background - As medication spending grows, Medicare Part D will need to adapt its coverage policies according to emerging evidence from a variety of insurance... 
Drugs | Health care costs | Economics, pharmaceutical | Statins | CHOLESTEROL-LOWERING THERAPY | economics, pharmaceutical | CARDIAC & CARDIOVASCULAR SYSTEMS | MEDICATIONS | drugs | PERSISTENCE | PROTON PUMP INHIBITORS | health care costs | IMPACT | OLDER PATIENTS | statins | ECONOMIC CONSEQUENCES | DISEASE | PERIPHERAL VASCULAR DISEASE | PRAVASTATIN | HEALTH | Drug Costs | Insurance Coverage - economics | Follow-Up Studies | Humans | National Health Programs - economics | Hydroxymethylglutaryl-CoA Reductase Inhibitors - economics | Male | British Columbia | Cost Sharing - economics | Insurance Coverage - statistics & numerical data | Deductibles and Coinsurance - statistics & numerical data | Insurance, Pharmaceutical Services - classification | Patient Compliance - statistics & numerical data | Insurance, Pharmaceutical Services - statistics & numerical data | Myocardial Infarction - drug therapy | Deductibles and Coinsurance - economics | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Aged, 80 and over | Female | Aged | Cost Sharing - statistics & numerical data | National Health Programs - statistics & numerical data | Cohort Studies | Insurance, Pharmaceutical Services - economics | Economic aspects | Influence | Dosage and administration | Research | Drug therapy | Prescription drug plans | Patient compliance | Heart attack
Journal Article
2007, 1st ed., ISBN 9780123739797, xx, 227 p., [3] p. of plates
Today, in the era of the statins (cholesterol lowering drugs), there is no longer any doubt about the value of lowering blood cholesterol levels. This book... 
Hypercholesteremia | Clinical & internal medicine | Hypercholesterolemia - drug therapy
Book
2011, 1st ed., ISBN 9780385535137, 385
Book
Arteriosclerosis, Thrombosis, and Vascular Biology: Journal of the American Heart Association, ISSN 1079-5642, 05/2003, Volume 23, Issue 5, pp. 729 - 736
ABSTRACT—The vascular endothelium is a dynamic endocrine organ that regulates contractile, secretory, and mitogenic activities in the vessel wall and... 
3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitor | Protein kinase Akt | Cholesterol | Atherosclerosis | Endothelium | atherosclerosis | protein kinase Akt | C-REACTIVE PROTEIN | PROGENITOR CELLS | endothelium | COA REDUCTASE INHIBITOR | CHOLESTEROL-LOWERING THERAPY | NITRIC-OXIDE SYNTHASE | ACUTE CORONARY SYNDROMES | SUPEROXIDE ANION PRODUCTION | VASCULAR SMOOTH-MUSCLE | cholesterol | PERIPHERAL VASCULAR DISEASE | LEUKOCYTE ADHESION | HEMATOLOGY | ARTERY DISEASE | Arteriosclerosis - etiology | Fibrinolysis - drug effects | Protein Prenylation - drug effects | Cholesterol - blood | Humans | Arteriosclerosis - physiopathology | Endothelium, Vascular - drug effects | Cell Adhesion - drug effects | Hypercholesterolemia - drug therapy | Vasoconstriction - drug effects | Anti-Inflammatory Agents, Non-Steroidal - pharmacology | Endothelium, Vascular - physiology | Naphthalenes - pharmacology | Arteriosclerosis - prevention & control | Anticholesteremic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Protein Processing, Post-Translational - drug effects | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Hypercholesterolemia - complications | Oxidative Stress - drug effects | Nitric Oxide - metabolism | Anticholesteremic Agents - pharmacology | Naphthalenes - therapeutic use
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 06/2013, Volume 15, Issue 6, pp. 513 - 522
Aims The objective was to assess the consistency of effect of switching to ezetimibe/simvastatin 10/20 mg versus doubling the baseline statin dose (to... 
clinical trial | cardiovascular disease | lipid‐lowering therapy | cholesterol‐lowering therapy | diabetes mellitus | dyslipidaemia | Cardiovascular disease | Clinical trial | Cholesterol-lowering therapy | Dyslipidaemia | Lipid-lowering therapy | Diabetes mellitus | ALTERING EFFICACY | HYPERCHOLESTEROLEMIA | MELLITUS | EZETIMIBE | ATORVASTATIN | lipid-lowering therapy | cholesterol-lowering therapy | HIGH-RISK | ENDOCRINOLOGY & METABOLISM | CORONARY-HEART-DISEASE | ROSUVASTATIN | Simvastatin - therapeutic use | Cardiovascular Diseases - drug therapy | Cardiovascular Diseases - prevention & control | Heptanoic Acids - therapeutic use | Humans | Middle Aged | Male | Apolipoproteins B - blood | Diabetes Mellitus, Type 1 - complications | Apolipoproteins B - drug effects | Metabolic Syndrome - drug therapy | Metabolic Syndrome - blood | Cardiovascular Diseases - blood | Adult | Cholesterol, LDL - blood | Female | Diabetic Angiopathies - prevention & control | Ezetimibe, Simvastatin Drug Combination | Drug Therapy, Combination | Pyrroles - therapeutic use | Diabetes Mellitus, Type 2 - complications | Fasting | Double-Blind Method | Drug Administration Schedule | Rosuvastatin Calcium | Cholesterol, LDL - drug effects | Treatment Outcome | Diabetic Angiopathies - blood | Diabetic Angiopathies - drug therapy | Metabolic Syndrome - complications | Diabetes Mellitus, Type 1 - drug therapy | Blood Glucose - drug effects | Atorvastatin Calcium | Diabetes Mellitus, Type 2 - blood | Anticholesteremic Agents - therapeutic use | Azetidines - therapeutic use | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Diabetes Mellitus, Type 1 - blood | Adolescent | Aged | Diabetes Mellitus, Type 2 - drug therapy | Drug Combinations | Fluorobenzenes - therapeutic use | Comparative analysis | Simvastatin | Low density lipoproteins | Cholesterol | Metabolic syndrome | Low density lipoprotein
Journal Article
Arteriosclerosis, Thrombosis, and Vascular Biology, ISSN 1079-5642, 03/2012, Volume 32, Issue 3, pp. 669 - 676
OBJECTIVE—Nicotinic acid (NA) treatment has been associated with benefits in atherosclerosis that are usually attributed to effects on plasma lipoproteins. The... 
atherosclerosis | macrophages | vascular biology | receptors | cholesterol-lowering drugs | LONG-TERM | INTEGRIN VLA-4 | ACTIVATION | DENDRITIC CELLS | KAPPA-B | FOAM CELLS | ENDOTHELIAL-CELLS | PERIPHERAL VASCULAR DISEASE | MICE | HEMATOLOGY | EXTENDED-RELEASE NIACIN | Tumor Necrosis Factor-alpha - metabolism | Phosphorylation | Integrin alpha4beta1 - metabolism | Toll-Like Receptor 2 - agonists | Human Umbilical Vein Endothelial Cells - metabolism | Receptors, G-Protein-Coupled - metabolism | Humans | Human Umbilical Vein Endothelial Cells - immunology | Monocytes - metabolism | Monocytes - immunology | Niacin - pharmacology | Receptors, Prostaglandin - metabolism | Receptors, Immunologic - antagonists & inhibitors | Inflammation - metabolism | Transfection | Chemotaxis, Leukocyte - drug effects | I-kappa B Kinase - metabolism | RNA Interference | Inflammation Mediators - metabolism | Toll-Like Receptor 4 - agonists | Chemokine CCL2 - metabolism | Receptors, G-Protein-Coupled - drug effects | Interleukin-6 - metabolism | Receptors, Prostaglandin - antagonists & inhibitors | Receptors, Nicotinic - drug effects | Receptors, Nicotinic - metabolism | Human Umbilical Vein Endothelial Cells - drug effects | Cyclooxygenase 2 Inhibitors - pharmacology | Anti-Inflammatory Agents - pharmacology | Cells, Cultured | Inflammation - immunology | Toll-Like Receptor 2 - metabolism | Cell Adhesion - drug effects | Toll-Like Receptor 4 - metabolism | Monocytes - drug effects | Transcription Factor RelA - metabolism | Lipopolysaccharides - pharmacology | Inflammation - genetics | Receptors, G-Protein-Coupled - genetics | Pyrazines - pharmacology | Vascular Cell Adhesion Molecule-1 - metabolism | Receptors, Nicotinic - genetics | Receptors, Immunologic - metabolism
Journal Article
Journal Article
Journal Article
Journal Article
Circulation, ISSN 0009-7322, 06/2002, Volume 105, Issue 25, pp. 3017 - 3024
Journal Article